Concepedia

Kristell Marzin

KM

Statistics

Publications

12

Citations

555

H-Index

10

Active since

2011

Affiliations

Boehringer Ingelheim (Germany)(Current)

Boehringer Ingelheim (United States)

Inserm

Institut Jules Bordet

UCLouvain

Kristell Marzin is an author at Boehringer Ingelheim (Germany) specializing in pharmacology, pharmacy, and pharmacokinetics.

Publications per year

2011–2025

12

Publications

12

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

Peter Stopfer, Kristell Marzin, H. Narjes et al. · Cancer Chemotherapy and Pharmacology · 2011 · 134 citations

, , +7

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

Peter Stopfer, Karin Rathgen, Daniel Bischoff et al. · Xenobiotica · 2011 · 79 citations

, , +13

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

Éric Pujade-Lauraine, Frédèric Selle, B. Weber et al. · Journal of Clinical Oncology · 2016 · 79 citations

, , +15

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Sven Wind, Arvid Jungnik, Tobias Brand et al. · Clinical Drug Investigation · 2014 · 60 citations

, , +12

Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

Claudia Dallinger, Dirk Trommeshauser, Kristell Marzin et al. · The Journal of Clinical Pharmacology · 2016 · 52 citations

, , +14

1–5 of 12